Genetics of Congenital Heart Disease (NCT01192048)
Genetic Testing of Individuals and Families With Congenital Heart Disease
π©Ί Plain-English Summary (8th-Grade Level)
Congenital heart disease (CHD) is the most common type of birth defect but the cause for the majority of cardiac birth defects remains unknown. Numerous epidemiologic studies have demonstrated evidence that genetic factors likely play a contributory, if not causative, role in CHD. While numerous genes have been identified by us and other investigators using traditional genetic approaches, these genes account for a minority of the non-syndromic CHDs. Therefore, we are now utilizing whole genome sequencing (WGS), with the addition of more traditional genetic techniques such as chromosomal microarray or traditional linkage analysis, to identify genetic causes of familial and isolated CHD. With WGS we are able to sequence all of the genetic material of an individual and apply different data analysis techniques based on whether we are analyzing a multiplex family or a cohort of trios (mother, father and child with CHD) with a specific isolated CHD. Therefore, WGS is a robust method for identification of novel genetic causes of CHD which will have important diagnostic and therapeutic consequences for these children.
Who can join: Review the eligibility criteria below.
Location: Nationwide Children's Hospital β Columbus, Ohio
π§ͺ Interventions in This Study
- Blood Sample Collection (OTHER)
π "Do I Qualify?" β 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria β
π All Participating Trial Locations (1 Sites)
- Nationwide Children's Hospital β Columbus, Ohio
π Contact the Study Coordinator
Phone: (614) 355-6388
Email: katherine.spayde@nationwidechildrens.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
π° Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Congenital Heart Disease
- Technical Development for Pediatric Cardiovascular MRI β Washington D.C., District of Columbia
- Harmony TPV Post-Approval Study β Birmingham, Alabama
- The Medtronic Harmonyβ’ Transcatheter Pulmonary Valve Clinical Study β Los Angeles, California
- Autus Valve Pivotal Study β Los Angeles, California
- Peer Coaching Intervention in Young Adults With Congenital Heart Disease β Durham, North Carolina
- SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure β Toronto, Ontario
Explore by condition: All Congenital Heart Disease clinical trials
π‘ How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.